Companion animal monoclonal antibodies are reshaping veterinary therapeutics. Zoetis's Librela for canine osteoarthritis pain and Solensia for feline OA pain together generated approximately $400 million in 2025 sales. In October 2025 Zoetis received Canadian approval for Leniva, a long-acting monoclonal antibody administered once every three months. Merck Animal Health's NUMELVI received FDA approval in February 2026 with U.S. spring 2026 commercial availability. Specialty biotech firms — Kindred Biosciences (Elanco), Scout Bio (Ceva), Aratana Therapeutics, and Invetx — are advancing pipeline candidates spanning dermatology, oncology, and chronic disease. The companion animal mAb addressable opportunity is estimated above $3 billion by 2030.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Companion Animal mAb Market Size, Growth and Forecast 2025-2030 by Indication
• Osteoarthritis Pain — Librela, Solensia, Leniva, and Pipeline Candidates
• Dermatology — JAK Inhibitors, Anti-IL-31, and Atopic Dermatitis Therapeutics
• Oncology — Lymphoma, Mast Cell Tumors, and Solid Tumor Pipelines
• Chronic Disease — CKD, Diabetes, and Cardiovascular Indications
• Regulatory Landscape — FDA CVM, EMA, and International Approval Pathways
• Manufacturing and Cold Chain — Biologics Production for Animal Health
• Competitive Landscape — Top 10 Pipelines + Specialty Biotech Entrants
• Investment and Partnership Opportunities — Licensing, Co-Development, JVs
• Market Challenges and Risks — Pricing, Reimbursement, Veterinary Adoption
Table of Contents
1. Executive Summary
2. Market Overview
3. Companion Animal mAb Market Size, Growth and Forecast 2025-2030
4. Osteoarthritis Pain Therapeutics
5. Dermatology Therapeutics
6. Oncology Therapeutics
7. Chronic Disease Therapeutics
8. Regulatory Landscape
9. Manufacturing and Cold Chain
10. Regional Analysis
11. Market Challenges and Risks
12. Competitive Landscape
13. Strategic Conclusions and Recommendations
14. Appendix
List of Tables
Table 1. Companion Animal mAb Market Size and Forecast 2025-2030 by Indication
Table 2. Approved Companion Animal Monoclonal Antibodies and Biologics 2025
Table 3. OA Pain Therapeutics — Librela, Solensia, Leniva Sales 2023-2025
Table 4. Dermatology mAb Pipeline by Supplier 2025
Table 5. Oncology Therapeutics Pipeline — Cancer Indications by Supplier
Table 6. Chronic Disease mAb Programs — CKD, Diabetes, Cardiovascular
Table 7. FDA CVM Approval Timeline and Regulatory Milestones 2024-2026
Table 8. Biologics Manufacturing Capacity by Supplier 2025
Table 9. Licensing and Co-Development Deals — Top 10 + Specialty Biotech
Table 10. Competitive Positioning by Indication and Pipeline Stage
Companies Profiled
Aratana Therapeutics
Boehringer Ingelheim Animal Health
Elanco Animal Health
Invetx
Kindred Biosciences
Merck Animal Health
Nexvet Biopharma
Scout Bio
Vetoquinol
Zoetis
